M Bayes, X Rabasseda, JR Prous - Methods and findings in …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP Mohana Priya,
M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G. Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
PA Sarafidis, GL Bakris - Kidney international, 2006 - nature.com The global epidemic of diabetes mellitus has led to a continuous increase in the prevalence
of diabetic nephropathy over the past years. Thus, diabetic nephropathy is currently the number
one cause of end-stage renal disease in the Western world. It represents a major public ... Cited by 72 - Related articles - BL Direct - All 4 versions
N Das Evcimen, GL King - Pharmacological research, 2007 - Elsevier Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in production
of insulin by the pancreas, and by resistance to insulin's effects. Such a deficiency results in increased
concentrations of glucose and other metabolites in the blood, which in turn damages ... Cited by 64 - Related articles - All 4 versions
Y Ohshiro, RC Ma, Y Yasuda, J Hiraoka-Yamamoto, … - Diabetes, 2006 - Am Diabetes Assoc Diabetes induces the activation of several protein kinase C (PKC) isoforms in the renal
glomeruli. We used PKC-β −/− mice to examine the action of PKC-β isoforms in diabetes-induced
oxidative stress and renal injury at 8 and 24 weeks of disease. Diabetes increased PKC ... Cited by 38 - Related articles - BL Direct - All 6 versions
- ►biovita.fi [PDF] JM Forbes, K Fukami, ME Cooper… - Experimental and Clinical …, 2007 - thieme-connect.com Diabetic nephropathy (DN), the most common cause of end stage renal disease in developed
nations, is thought to result from interactions between metabolic and haemodynamic factors.
Specific metabolically driven, glucose dependent pathways are activated within diabetic ... Cited by 36 - Related articles - BL Direct - All 7 versions
SM Marshall - Current pharmaceutical design, 2007 - ingentaconnect.com Abstract: Over the last five years, much work has underlined the important role of the podocyte
in the development of diabetic neph- ropathy. The metabolic and haemodynamic abnormalities
of the diabetic milieu act in concert, perhaps via the common effector path of oxidative ... Cited by 25 - Related articles - BL Direct - All 4 versions
C Sánchez, C Méndez, JA Salas - Natural Product Reports, 2006 - rsc.org The indolocarbazole family of natural products, including the biosynthetically related
bisindolylmaleimides, is reviewed (with 316 references cited). The isolation of indolocarbazoles
from natural sources and the biosynthesis of this class of compounds are thoroughly ... Cited by 23 - Related articles - BL Direct - All 5 versions
JB McGill, GL King, PH Berg, KL Price, KA … - Expert Opin. Drug …, 2006 - informahealthcare.com The aim of this manuscript is to report the safety profile of patients treated with ruboxistaurin mesylate
(RBX; LY333531), a selective protein kinase C-β (PKC-β) inhibitor, for up to 4 years. Data from
patients with diabetes (1396 RBX 32 mg/day; 1408 placebo) were combined from 11 ... Cited by 22 - Related articles - BL Direct - All 5 versions
Y Zhu, HK Usui, K Sharma - Seminars in nephrology, 2007 - pubmedcentral.nih.gov The recognition of the drivers of matrix accumulation as a therapeutic target for diabetic nephropathy
is accepted by the Nephrology and pharmaceutical community. Interventions focused around
Transforming Growth Factor–beta (TGF–β) will likely be an important area of clinical ... Cited by 21 - Related articles - All 9 versions
A Avignon, A Sultan - Diabetes and Metabolism, 2006 - Elsevier PKC comprises a superfamily of isoenzymes that is activated in response to various stimuli. Hyperglycaemia
induces the activation of different PKC isoforms. However, the PKC-β isoform appears to be preferentially
activated by high glucose levels and has been shown to be associated with diabetic ... Cited by 21 - Related articles - BL Direct - All 3 versions
